Key Highlights
- On April 7, 2026, private equity firms Blackstone and TPG completed their acquisition of Hologic at $79 per share maximum value.
- Shareholders obtained $76 cash per share alongside a contingent value right potentially worth an additional $3, dependent on Breast Health division performance.
- Abu Dhabi Investment Authority and GIC participated as minority investors in the transaction.
- Following 12+ years of leadership, CEO Stephen MacMillan stepped down, with Joe Almeida taking the helm.
- Trading of HOLX shares has concluded, with Nasdaq delisting proceedings underway.
The women’s health technology company Hologic completed its transition to private ownership on April 7, 2026, marking the successful conclusion of a significant acquisition by investment firms Blackstone and TPG at a maximum valuation of $79 per share.
Originally unveiled to the market on October 21, 2025, the buyout secured stockholder backing on February 5, 2026. The deal structure also incorporated strategic minority stakes from Abu Dhabi Investment Authority’s subsidiary and a GIC-affiliated entity.
Investors collected $76 cash for each share they owned. Additionally, they received a contingent value right that cannot be traded, potentially delivering up to $3 more per share through two separate $1.50 payments. These payments depend entirely on whether the company achieves specific worldwide revenue benchmarks within its Breast Health segment during fiscal 2026 and 2027.
The contingent payment mechanism means shareholders will only realize the complete $79 valuation if Hologic satisfies those performance criteria. This represents an important consideration for those analyzing the transaction’s ultimate worth.
Prior to the deal’s finalization, Hologic posted trailing twelve-month revenues of $4.13 billion, maintained a 60% gross margin, and demonstrated a current ratio exceeding 4. The firm’s market capitalization stood at $16.97 billion.
The company’s latest quarterly performance fell below market projections. Quarterly revenue reached $1.05 billion against analyst expectations of $1.07 billion, while adjusted earnings per share came in at $1.04 versus the anticipated $1.09.
Executive Transition
Stephen MacMillan concluded his tenure as Chief Executive Officer upon deal closure, wrapping up over twelve years of leadership. Joe Almeida immediately assumed the CEO position and was simultaneously appointed as the company’s sole board director.
Almeida brings extensive medical technology industry experience. He most recently led Baxter International as Chairman, President and CEO from 2016 through early 2025. Prior to that appointment, he held identical executive roles at Covidien before its 2015 acquisition by Medtronic.
This executive restructuring reflects the strategic priorities of the new ownership group — Blackstone, overseeing $1.3 trillion in assets under management, and TPG, managing $303 billion — as they pursue expansion objectives under private ownership.
The acquisition also triggered comprehensive changes to Hologic’s equity compensation framework. Employee stock options and equity-based awards received settlement through various combinations of cash payments and contingent value rights, while out-of-the-money options were terminated without compensation.
Market Exit Complete
Public trading of HOLX shares has officially concluded. Delisting procedures from Nasdaq are proceeding, transforming the company into a completely owned entity of the Blackstone-TPG investment group.
Shares finished their final trading session at $76.01 — nearly matching the 52-week peak of $76.07, demonstrating how accurately market participants anticipated the transaction’s successful completion.
Ahead of the acquisition’s finalization, six Wall Street analysts adjusted their earnings projections downward for future reporting periods. The final published analyst recommendation on HOLX maintained a Buy rating with an $83 price objective.
Before the deal closed, InvestingPro had evaluated Hologic’s financial condition with a “GREAT” overall health rating.
